T
Tanja Stamm
Researcher at Medical University of Vienna
Publications - 346
Citations - 12137
Tanja Stamm is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 47, co-authored 271 publications receiving 9937 citations. Previous affiliations of Tanja Stamm include Ludwig Maximilian University of Munich & Health Science University.
Papers
More filters
Journal ArticleDOI
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Josef S Smolen,Ferdinand C. Breedveld,Gerd R Burmester,Vivian P. Bykerk,Maxime Dougados,Paul Emery,Tore K Kvien,M Victoria Navarro-Compán,Susan Oliver,Monika Schoels,Marieke Scholte-Voshaar,Tanja Stamm,Michaela Stoffer,Tsutomu Takeuchi,Daniel Aletaha,Jose Louis Andreu,Martin Aringer,Martin J. Bergman,Neil Betteridge,H. Bijlsma,Harald Burkhardt,Mario H. Cardiel,Bernard Combe,Patrick Durez,João Eurico Fonseca,A. Gibofsky,Juan J. Gomez-Reino,Winfried Graninger,Pekka Hannonen,Boulos Haraoui,Marios Kouloumas,Robert Landewé,Emilio Martín-Mola,Peter Nash,Mikkel Østergaard,Andrew J. K. Östör,Pam Richards,T. Sokka-Isler,Carter Thorne,Athanasios G. Tzioufas,Ronald F van Vollenhoven,Martinus de Wit,Désirée van der Heijde +42 more
TL;DR: The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
Journal ArticleDOI
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
Daniel Aletaha,Valerie Nell,Tanja Stamm,Martin Uffmann,Stephan Pflugbeil,Klaus P Machold,Josef S Smolen +6 more
TL;DR: A purely clinical score is a valid measure of disease activity and will have its greatest merits in clinical practice rather than research, where APRs are usually always available.
Journal ArticleDOI
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis
TL;DR: There is a window of opportunity for highly successful treatment of RA in the first year, and especially within the first 3 months of therapy, indicating that early diagnosis and therapy may be the crucial step in achieving optimal control of disease progression and prognosis in RA.
Journal ArticleDOI
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S. Smolen,Monika Schöls,Jürgen Braun,Maxime Dougados,Oliver FitzGerald,Dafna D. Gladman,Arthur Kavanaugh,Robert Landewé,Philip J. Mease,Joachim Sieper,Tanja Stamm,Maarten de Wit,Daniel Aletaha,Xenofon Baraliakos,Neil Betteridge,Filip Van den Bosch,Laura C. Coates,Paul Emery,Lianne S. Gensler,Laure Gossec,Philip S. Helliwell,Merryn Jongkees,Tore K Kvien,Robert D. Inman,Iain B. McInnes,Mara Maccarone,Pedro Machado,Anna Molto,Alexis Ogdie,Denis Poddubnyy,Christopher T. Ritchlin,Martin Rudwaleit,Adrian Tanew,Bing Thio,Douglas J. Veale,Kurt de Vlam,Désirée van der Heijde +36 more
TL;DR: There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA.
Journal ArticleDOI
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.
Daniel Aletaha,Daniel Aletaha,Daniel Aletaha,Michael M. Ward,Klaus P Machold,Valerie Nell,Tanja Stamm,Josef S Smolen +7 more
TL;DR: New criteria for levels of RA disease activity were determined and internally validated based on current and explicit expert judgment, which are valuable in this era of rapidly advancing therapeutic approaches.